跳至主要内容
临床试验/NCT01528514
NCT01528514已完成不适用

The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study

Wanwarang Wongcharoen, MD.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2009年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
1
主要终点
Incidence of postoperative myocardial infarction

研究概览

简要总结

It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Patients undergoing CABG without valve surgery

排除标准

  • •emergency cardiac surgery
  • •any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
  • •patients with cholestatic jaundice (total bilirubin > 2-fold ULN)
  • •severe liver disease (AST or ALT > 3-fold ULN)

研究组 & 干预措施

Curcuminoids

Active Comparator

干预措施: Curcuminoids (Dietary Supplement)

Placebo

Placebo Comparator

干预措施: Placebo (Other)

结局指标

主要结局

Incidence of postoperative myocardial infarction

时间窗: participants will be followed for the duration of hospital stay, an expected average of 10 days

次要结局

未报告次要终点

研究者

发起方
Wanwarang Wongcharoen, MD.
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Wanwarang Wongcharoen, MD.

Principal investigator

Thailand Research Fund

研究点 (1)

Loading locations...

相似试验